Acta Epileptologica最新文献

{"title":"Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database.","authors":"Jianxiong Gui, Lingman Wang, Linxue Meng, Xiaofang Zhang, Jiannan Ma, Li Jiang","doi":"10.1186/s42494-025-00223-5","DOIUrl":"10.1186/s42494-025-00223-5","url":null,"abstract":"<p><strong>Background: </strong>Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.</p><p><strong>Methods: </strong>This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).</p><p><strong>Results: </strong>A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.</p><p><strong>Conclusions: </strong>This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"31"},"PeriodicalIF":1.2,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seizure frequency, APOE ε4, and cognitive function in older people with epilepsy.","authors":"Yiling Chen, Zhenxu Xiao, Xiaowen Zhou, Saineng Ding, Luxin Jiang, Qianhua Zhao, Ding Ding, Jianhong Wang, Guoxing Zhu","doi":"10.1186/s42494-025-00213-7","DOIUrl":"10.1186/s42494-025-00213-7","url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment represents a major comorbidity among older adults with epilepsy. This study aimed to explore the association between the apolipoprotein E (APOE) ε4 allele and cognitive function in older people with epilepsy.</p><p><strong>Methods: </strong>People with epilepsy aged ≥ 50 years were enrolled at an outpatient clinic of epilepsy from November 2019 to July 2024. Blood samples were collected for APOE genotyping. Participants were categorized into two groups based on the presence of the APOE ε4 allele: APOE ε4 (+/-). Cognitive function was assessed using a battery with neuropsychological tests. Based on Mini-Mental State Examination (MMSE) scores, participants were defined as unimpaired cognition (UC) (MMSE ≥ 27) and cognitive impairment (CI) (MMSE < 27). Seizure frequency was categorized into low (≤ 3/year) and high (> 3/year) groups. Multivariate logistic regression analysis and general linear models were employed to identify factors associated with cognitive function.</p><p><strong>Results: </strong>Among 110 participants, 51 (46.4%) were defined as CI. Compared with UC group, the CI group was older (65.1 ± 7.6 vs 60.8 ± 6.8 years, P = 0.002), with lower educational level (9.0 [7.0, 11.0] vs 12.0 [9.0, 13.0] years, P < 0.001), and higher seizure frequency (12.0 [1.0, 24.0] vs 1.0 [0.0, 12.0] times/year, P = 0.005). High seizure frequency (OR = 3.94, 95% CI [1.34, 11.61], P = 0.013) and more APOE ε4 alleles (OR = 3.28, 95% CI [1.09, 9.83], P = 0.034) were risk factors for CI. An interactive effect between the number of APOE ε4 alleles and seizure frequency was observed (P = 0.002). Compared to participants with APOE ε4 (-) and low seizure frequency, those with APOE ε4 (-) and high seizure frequency showed a threefold risk of CI (OR = 3.34, 95% CI [0.99, 11.25], P = 0.051), while those with APOE ε4 (+) and high frequency demonstrated the highest risk of CI (OR = 10.53, 95% CI [1.75, 63.47], P = 0.010).</p><p><strong>Conclusions: </strong>The synergistic effect of APOE ε4 allele and seizure frequency on cognitive function suggested their importance in clinical assessments and therapeutic approaches in managing older people with epilepsy.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"30"},"PeriodicalIF":1.2,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on epilepsy with myoclonic absence.","authors":"Fen Tang, Minting Li, Liangmin Liu, Xuemei Wang, Bing Qin","doi":"10.1186/s42494-025-00218-2","DOIUrl":"10.1186/s42494-025-00218-2","url":null,"abstract":"<p><p>Epilepsy with myoclonic absence (EMA) is a rare childhood-onset generalized epilepsy syndrome characterized by myoclonic absence seizures. First discovered by Tassinari et al. in 1969, EMA has been extensively studied by researchers from all over the world. This review synthesizes recent studies on EMA, covering its discovery history, classification, epidemiology, pathophysiology, etiology, clinical manifestations, diagnosis and differential diagnosis, treatment, prognosis and evolution, and especially discusses the etiology and pathophysiology mechanism, to help clinicians understand this relatively rare epilepsy syndrome, reduce the rate of missed diagnosis and misdiagnosis, and effectively guide treatment to alleviate the long-term cognitive impairment in affected individuals.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"29"},"PeriodicalIF":1.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of vagus nerve stimulation in patients with drug-resistant epilepsy: a single center experience.","authors":"Ebtehal Alwazna, Jamal Abdullah, Hanin Alsini, Marahib Alshahrani, Wafa Aldhafeeri, Alawi Al-Attas, Abeer Alshaikh, Mashael Alanazi, Hamoud Alsahli, Mohammed Alshahrani, Shatha Alshafi, Brahim Tabarki, Abdulrahman Nazer, Sonia Khan","doi":"10.1186/s42494-025-00215-5","DOIUrl":"https://doi.org/10.1186/s42494-025-00215-5","url":null,"abstract":"<p><strong>Background: </strong>Drug-resistant epilepsy (DRE) exerts substantial clinical, humanistic and economic burdens on patients, their families and the healthcare system. Vagus nerve stimulation (VNS) has been extensively tested in clinical trial settings to decrease the frequency of seizures in patients with DRE who are not candidates for surgery; the results indicate promising efficacy and a well-tolerated safety profile. However, real-world evidence is still lacking. This retrospective study evaluated the safety and efficacy of VNS in patients with DRE.</p><p><strong>Methods: </strong>The current study was a retrospective chart review of the medical records of children and adults with DRE treated with VNS between December 2006 and November 2022. The primary outcome of the present study was the percentage of patients who experienced a reduction in seizure frequency of more than 50% compared with the frequency at baseline (the period before VNS device insertion).</p><p><strong>Results: </strong>A total of 103 patients were included. The percentage of patients who achieved a reduction of more than 50% in seizure frequency was 23% at six months, 36% at 12 months, 65% at 18 months, and 72% at 24 months. Similarly, the percentage of patients with complete resolution of interictal epileptiform discharges (IEDs) increased from 30% at six months to 60% after 24 months. The overall Quality of Life in Epilepsy (QOLIE-31) score at the end of follow-up was 39.46 ± 13.68 points. Two patients (1.9%) reported experiencing side effects at the end of follow-up.</p><p><strong>Conclusions: </strong>VNS implementation led to a significant reduction in the seizure frequency and resolution of IEDs, with a well-tolerated safety profile. The findings highlight the potential role of VNS in managing DRE and warrant its consideration for treating patients with DRE.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"28"},"PeriodicalIF":1.2,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: late adverse reactions in an epilepsy patient on combination therapy with valproate and lamotrigine.","authors":"Hui Sang, Liqiao Zhao, Yanhua Zhang, Xiaolong Wang, Xiaodong Zhang","doi":"10.1186/s42494-025-00217-3","DOIUrl":"https://doi.org/10.1186/s42494-025-00217-3","url":null,"abstract":"<p><strong>Background: </strong>Late adverse reactions associated with the combined therapy of valproate and lamotrigine are infrequently documented within the Chinese population.</p><p><strong>Case presentation: </strong>This case report describes a 54-year-old female patient who developed adverse reactions following long-term therapy with valproate and lamotrigine, with symptoms emerging five months after the final adjustment of her antiseizure regimen. The patient presented with symptoms of dizziness, ataxia, nystagmus, and postural tremors. Following blood drug concentration monitoring and subsequent minor dosage adjustments to the antiseizure regimen without medication withdrawal, the patient's symptoms were successfully resolved.</p><p><strong>Conclusions: </strong>This article underscores the importance of vigilance among clinicians regarding the potential for late adverse reactions and advocates for the proactive monitoring of blood drug concentrations.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"27"},"PeriodicalIF":1.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parenchymal neuro-sonological characteristics in epileptic patients and their correlation with cognitive dysfunction.","authors":"Hanan Amer, Hanan Helmy, Enji El-Sawy, Maha S Ayoub, Nesma Mounir","doi":"10.1186/s42494-025-00212-8","DOIUrl":"https://doi.org/10.1186/s42494-025-00212-8","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic generalized epilepsies (IGEs) are the most common syndromes within the \"genetic generalized epilepsies\" (GGEs). Patients with IGE often exhibit cognitive comorbidities. The primary objective of this study is to investigate the correlation between brain parenchymal sonography characteristics and cognitive impairment in IGE.</p><p><strong>Methods: </strong>This study enrolled 26 patients with IGE and 26 age- and sex-matched controls. All participants underwent comprehensive evaluations including clinical examination, electroencephalography, magnetic resonance imaging epilepsy protocol, transcranial sonography (TCS) for third and lateral ventricular diameter measurements, and cognitive assessment using the Addenbrooke's Cognitive Examination-III (ACE III).</p><p><strong>Results: </strong>This study found significantly lower scores in attention, memory, fluency, and total score of ACE-III in IGE patients compared to the control group (P-value = 0.011, 0.033, 0.007, and 0.001, respectively). However, no significant differences were observed between IGE patients and the control group in language and visuospatial score (P = 0.479 and 0.108, respectively). The average diameters of the third ventricle and lateral ventricle anterior horns were significantly larger in patients than in the control group (P-value 0.004, 0.009, and 0.012, respectively).</p><p><strong>Conclusions: </strong>IGE patients exhibit significant cognitive impairment and notable dilatation of the third ventricle and lateral ventricles horns, which may serve as markers of brain atrophy.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"26"},"PeriodicalIF":1.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnosis and treatment of disorders of nucleic acid/nucleotide metabolism associated with epilepsy.","authors":"Yuqing Shi, Zihan Wei, Yan Feng, Yajing Gan, Guoyan Li, Yanchun Deng","doi":"10.1186/s42494-025-00201-x","DOIUrl":"https://doi.org/10.1186/s42494-025-00201-x","url":null,"abstract":"<p><p>Epilepsy is a prevalent paroxysmal disorder in the field of neurology. Among the six etiologies of epilepsy, metabolic causes are relatively uncommon in clinical practice. Metabolic disorders encompass amino acid metabolism disorders, organic acid metabolism disorders, and other related conditions. Seizures resulting from nucleic acid/nucleotide metabolism disorders are even more infrequent. This review provides an overview of several studies on nucleic acid/nucleotide metabolism disorders associated with epilepsy, including adenosine succinate lyase deficiency, Lesch-Nyhan syndrome, and aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) deficiency, among others. The potential pathogenesis, phenotypic features, diagnostic pathways, and therapeutic approaches of these diseases are discussed in this review. The goal is to help clinicians make an accurate diagnosis when encountering rare nucleic acid/nucleotide metabolism disorders with multi-system symptoms and manifestations of epilepsy.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"23"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative analysis of the resting-state EEG power spectrum in patients with epilepsy comorbid with anxiety and depression.","authors":"Hongxing Chen, Juan Yang, Bo Zhang, Lijia Zhang, Jing Wang, Haiqing Zhang, Hongwei Zhang, Changyin Yu, Jun Zhang, Zucai Xu","doi":"10.1186/s42494-025-00206-6","DOIUrl":"https://doi.org/10.1186/s42494-025-00206-6","url":null,"abstract":"<p><strong>Background: </strong>Epilepsy is one of the common clinical disorders with comorbid anxiety and depression that severely affects their quality of life and increases their suicidality, while screening for anxiety and depression currently lacks objective identifiers. This study aimed to analyze the characteristics of the electroencephalogram (EEG) power spectrum in patients with epilepsy with comorbid anxiety and depression, utilizing resting EEG data.</p><p><strong>Methods: </strong>Resting EEG data were collected under standard conditions from two groups: patients with epilepsy comorbid with anxiety and depression (n = 42) and patients without comorbidities (n = 45). EEG power was calculated using data processing with EEGLAB and MATLAB. This study compared the absolute and relative powers of the δ, θ, α, β, and γ frequency bands, as well as the values of (δ + θ)/(α + β), between the two groups. Additionally, the correlation between the EEG power of each frequency band and anxiety and depression scores was analyzed.</p><p><strong>Results: </strong>1) Among individuals with epilepsy comorbid with anxiety and depression, lower absolute power of δ, α, and θ at specific sites was observed (P < 0.05), along with lower relative power of θ at certain sites (P < 0.05). Conversely, higher relative power of β and γ at specific sites was noted in those with comorbidities (P < 0.05). 2) There was no statistically significant difference in the values of (δ + θ)/(α + β) between the two groups (P > 0.05). 3) Depression scores exhibited a negative correlation with θ absolute power at the T3 and T4 sites (P < 0.05), while showing a positive correlation with β relative power at the C4 and T6 sites (P < 0.05). Anxiety scores displayed a positive correlation with β relative power at the F4, C3, C4 and T6 sites and γ relative power at F8 site (P < 0.05).</p><p><strong>Conclusions: </strong>The findings suggest that comorbid anxiety and depression may impact resting EEG power spectra in individuals with epilepsy, particularly in regions exhibiting altered network connectivity. Furthermore, a positive correlation was observed between anxiety and depression scores and β relative power in the right central and right posterior temporal regions, indicating potential screening utility.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"22"},"PeriodicalIF":1.2,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of active convulsive epilepsy in Dunukofia County in South East Nigeria: a door-to-door survey.","authors":"Obiora Daniel Anaje, Paul Osemeke Nwani, Maduaburochukwu C Nwosu, Lasbrey Azuoma Asomugha, Chetanna Chioma Anaje, Ifeoma Adaigwe Amaechi, Uzoamaka Nwakaego Akobundu, Olisaeloka Ginikachi Ebeogu, Linda Ifunanya Eze, Nnamdi Joseph Morah, Sunday Onyemaechi Oriji, Chinwe Chioma Ndukwe, Imelda Chinenye Omaga, Adesola Ogunniyi","doi":"10.1186/s42494-024-00200-4","DOIUrl":"https://doi.org/10.1186/s42494-024-00200-4","url":null,"abstract":"<p><strong>Background: </strong>Regional variations in the prevalence of epilepsy in Nigeria have been validated. We determined the prevalence of active convulsive epilepsy in six towns of Dunukofia County and compared the findings with existing regional prevalence data.</p><p><strong>Methods: </strong>Patients with active convulsive epilepsy were identified in a two-phase cross-sectional descriptive community-based door-to-door study using a validated questionnaire in the first phase and a modified epilepsy questionnaire developed for tropical countries in the second phase after clinical assessment and electroencephalogram.</p><p><strong>Results: </strong>A total of 9000 persons were surveyed in the first stage, of which 56 had active convulsive epilepsy. The highest point prevalence was found in Nawgu, 7.3 per 1000 (95% confidence interval [CI]: 2.7-15.8) while the lowest point prevalence of 5.0 per 1000 (95% CI: 2.0-10.3) was obtained in Ukpo. The observed rates after age adjustment to the Nigeria standard population of 4.9-5.7 per 1000 in this study, which was comparable to 4.6-5.7 per 1000 reported in previous studies, besides two isolated reports of rates as low as 2.7 per 1000 and as high as 20.0 per 1000 reported in the past from two sites in the northern section of the region.</p><p><strong>Conclusions: </strong>The burden of epilepsy is high in this region, and intra-regional differences in prevalence rates exist. The implications of this finding do not only border on the care of people living with epilepsy but also highlight the need to identify local risk factors as well as appropriate and locally acceptable approaches to reduce the epilepsy burden.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"21"},"PeriodicalIF":1.2,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of cannabidiol for seizures reduction in pharmacoresistant epilepsy: a systematic review and meta-analysis.","authors":"Vinícius Gabino de Oliveira, Natália Brito de Almeida, Guilherme Corrêa Radmann, Bruno Fernandes de Oliveira Santos","doi":"10.1186/s42494-024-00191-2","DOIUrl":"https://doi.org/10.1186/s42494-024-00191-2","url":null,"abstract":"<p><strong>Background: </strong>Epilepsy is a neurological syndrome caused by excessive neuronal discharges, with a part of the patients being pharmacoresistant to the traditional treatment. Cannabidiol, a non-psychoactive component of Cannabis Sativa, shows promise as an alternative, but further research is needed to quantify its efficacy.</p><p><strong>Methods: </strong>This literature systematic review was made following the PRISMA protocol guidelines. The Google Scholar, Scielo, and PubMed/MEDLINE databases were included using the descriptors \"Cannabidiol\", \"Epilepsy\", and \"Drug Resistant Epilepsy\". This research was registered in the Prospero platform with the identification (CRD42024479643).</p><p><strong>Results: </strong>A total of 1448 results were identified from the PubMed, Virtual Health Library, and Google Scholar databases. After applying exclusion criteria, six studies met the criteria for full-text evaluation and eligibility. The compiled analysis showed that the patients who received cannabidiol experienced a 41.0875% reduction in the total number of seizures, compared to an average reduction of 18.1% in placebo groups. This represents a 127% higher response rate for patients who received the intervention.</p><p><strong>Conclusions: </strong>Given these results, it is possible to conclude that the therapeutic response of cannabidiol is worthy of consideration in new protocols and of being added to public healthcare systems for its antiepileptic potential. However, the high efficacy rate observed in the placebo group suggests that other methods of data collection analysis may be employed.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"20"},"PeriodicalIF":1.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}